Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Basic): 2015-2025

Historic EPS (Basic) for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$1.38.

  • Cartesian Therapeutics' EPS (Basic) fell 22.12% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.42, marking a year-over-year increase of 97.30%. This contributed to the annual value of -$4.48 for FY2024, which is 91.00% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' EPS (Basic) stood at -$1.38, which was down 370.59% from $0.51 recorded in Q2 2025.
  • Cartesian Therapeutics' EPS (Basic)'s 5-year high stood at $0.58 during Q2 2024, with a 5-year trough of -$41.56 in Q4 2023.
  • Over the past 3 years, Cartesian Therapeutics' median EPS (Basic) value was -$1.38 (recorded in 2025), while the average stood at -$5.66.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 204.55% in 2022, then crashed by 138,633.33% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' EPS (Basic) (Quarterly) stood at $0.12 in 2021, then plummeted by 75.00% to $0.03 in 2022, then tumbled by 138,633.33% to -$41.56 in 2023, then spiked by 100.31% to $0.13 in 2024, then decreased by 22.12% to -$1.38 in 2025.
  • Its last three reported values are -$1.38 in Q3 2025, $0.51 for Q2 2025, and -$0.68 during Q1 2025.